Supreme Court declines to hear IRA challenges from Novo, AZ and more

Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers continue to fight Medicare price negotiations under the Biden-era Inflation | Following a string of defeats for the industry in challenging the Inflation Reduction Act, Hail Mary efforts from a handful of companies to have their criticisms heard by the United States’ High Court have fallen flat.